Joseph Mikhael, MD, MEd, discusses the potential and limitations of at-home cancer care using on-body injection technology.

Community oncology expands hereditary cancer genetic testing with team-based counseling, trained clinicians, and structured ...

AI-built social posts aim to raise young women’s awareness that alcohol increases breast cancer risk, while a trial tracks ...

A Big Ten Cancer Research Consortium project is testing counter-marketing, plain-language messages tailored for social media ...

The 2026 National Comprehensive Cancer Network (NCCN) guidelines now separate HER2– disease further, into HER2 null (no membrane staining at all), HER2 ultra-low (IHC 0 with faint, incomplete membrane ...

Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients. In part 2 of this interview, Joyce Ohm, PhD, explains ...

Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the ...

Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the ...

Betts, MD, discusses how PTCy and tacrolimus protocols, as well as using younger donors, contributes to higher survival rates ...

Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...

FDA approval covers post–ROS1 inhibitor locally advanced/metastatic ROS1-positive NSCLC, granted ahead of the September 18, 2026 PDUFA date with breakthrough therapy and orphan drug designations.

FDA accepted an NDA for daraxonrasib in previously treated metastatic PDAC, supported by RASolute 302 and prior breakthrough therapy and orphan drug designations. Phase 3 RASolute 302 showed OS nearly ...